ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

18 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

12 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

10 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

07 Nov 2024 15:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces November Investor Conference Participation

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

01 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

08 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

06 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

31 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

31 Jul 2024 04:30:00 By Nasdaq GlobeNewswire

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

02 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

29 May 2024 08:00:01 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 15:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Allison Dillon as Chief Business Officer

07 May 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

30 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire